Department of Urology, Boston Children's Hospital, Boston, Massachusetts.
Department of Surgery, Harvard Medical School, Boston, Massachusetts.
Am J Physiol Renal Physiol. 2020 Apr 1;318(4):F901-F910. doi: 10.1152/ajprenal.00496.2019. Epub 2020 Mar 2.
The signaling pathways and effectors that drive the response of the bladder to nonmalignant insults or injury are incompletely defined. Interrogation of biological systems has been revolutionized by the ability to generate high-content data sets that capture information on a variety of biomolecules in cells and tissues, from DNA to RNA to proteins. In oncology, such an approach has led to the identification of cancer subtypes, improved prognostic capability, and has provided a basis for precision treatment of patients. In contrast, systematic molecular characterization of benign bladder disorders has lagged behind, such that our ability to uncover novel therapeutic interventions or increase our mechanistic understanding of such conditions is limited. Here, we discuss existing literature on the application of omics approaches, including transcriptomics and proteomics, to urinary tract conditions characterized by pathological tissue remodeling. We discuss molecular pathways implicated in remodeling, challenges in the field, and aspirations for omics-based research in the future.
驱动膀胱对非恶性刺激或损伤产生反应的信号通路和效应器尚未完全确定。通过生成能够捕获细胞和组织中各种生物分子(从 DNA 到 RNA 再到蛋白质)信息的高内涵数据集,对生物系统的研究已经发生了革命性的变化。在肿瘤学领域,这种方法已经导致了癌症亚型的鉴定、预后能力的提高,并为患者的精准治疗提供了基础。相比之下,良性膀胱疾病的系统分子特征描述却落后了,因此,我们发现新的治疗干预措施或提高对这些疾病的机制理解的能力受到了限制。在这里,我们讨论了应用组学方法(包括转录组学和蛋白质组学)来研究以病理性组织重塑为特征的泌尿道疾病的现有文献。我们讨论了重塑过程中涉及的分子途径、该领域的挑战,以及未来基于组学的研究的期望。